Currently, crizotinib is being evaluated as a first-line agent over platinum-pemetrexed chemotherapy in phase III PROFILE 1014 study to treat ALK-positive NSCLC (Table 2). The gene discussed is ALK; the disease is non-small cell lung carcinoma.